152 related articles for article (PubMed ID: 21440023)
1. Blockade of enzyme activity inhibits tissue transglutaminase-mediated transamidation of α-synuclein in a cellular model of Parkinson's disease.
Verhaar R; Jongenelen CA; Gerard M; Baekelandt V; Van Dam AM; Wilhelmus MM; Drukarch B
Neurochem Int; 2011 Jun; 58(7):785-93. PubMed ID: 21440023
[TBL] [Abstract][Full Text] [Related]
2. Increase in endoplasmic reticulum-associated tissue transglutaminase and enzymatic activation in a cellular model of Parkinson's disease.
Verhaar R; Drukarch B; Bol JG; Jongenelen CA; Musters RJ; Wilhelmus MM
Neurobiol Dis; 2012 Mar; 45(3):839-50. PubMed ID: 22051113
[TBL] [Abstract][Full Text] [Related]
3. Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease.
Andringa G; Lam KY; Chegary M; Wang X; Chase TN; Bennett MC
FASEB J; 2004 May; 18(7):932-4. PubMed ID: 15001552
[TBL] [Abstract][Full Text] [Related]
4. Tissue transglutaminase cross-links beclin 1 and regulates autophagy in MPP⁺-treated human SH-SY5Y cells.
Verhaar R; Drukarch B; Bol JG; Jongenelen CA; Wilhelmus MM
Neurochem Int; 2013 Mar; 62(4):486-91. PubMed ID: 23380076
[TBL] [Abstract][Full Text] [Related]
5. Tissue transglutaminase modulates alpha-synuclein oligomerization.
Segers-Nolten IM; Wilhelmus MM; Veldhuis G; van Rooijen BD; Drukarch B; Subramaniam V
Protein Sci; 2008 Aug; 17(8):1395-402. PubMed ID: 18505736
[TBL] [Abstract][Full Text] [Related]
6. Complex formation between tissue transglutaminase II (tTG) and vascular endothelial growth factor receptor 2 (VEGFR-2): proposed mechanism for modulation of endothelial cell response to VEGF.
Dardik R; Inbal A
Exp Cell Res; 2006 Oct; 312(16):2973-82. PubMed ID: 16914140
[TBL] [Abstract][Full Text] [Related]
7. Tissue transglutaminase is not involved in the aggregate formation of stably expressed alpha-synuclein in SH-SY5Y human neuroblastoma cells.
Suh MD; Park CH; Kim SS; Kil MO; Lee GH; Johnson GV; Chun W
Arch Pharm Res; 2004 Aug; 27(8):850-6. PubMed ID: 15460447
[TBL] [Abstract][Full Text] [Related]
8. Presence of tissue transglutaminase in granular endoplasmic reticulum is characteristic of melanized neurons in Parkinson's disease brain.
Wilhelmus MM; Verhaar R; Andringa G; Bol JG; Cras P; Shan L; Hoozemans JJ; Drukarch B
Brain Pathol; 2011 Mar; 21(2):130-9. PubMed ID: 20731657
[TBL] [Abstract][Full Text] [Related]
9. A cell-based model of alpha-synucleinopathy for screening compounds with therapeutic potential of Parkinson's disease.
Zhao DL; Zou LB; Zhou LF; Zhu P; Zhu HB
Acta Pharmacol Sin; 2007 May; 28(5):616-26. PubMed ID: 17439717
[TBL] [Abstract][Full Text] [Related]
10. Heat shock proteins reduce alpha-synuclein aggregation induced by MPP+ in SK-N-SH cells.
Fan GH; Zhou HY; Yang H; Chen SD
FEBS Lett; 2006 May; 580(13):3091-8. PubMed ID: 16678164
[TBL] [Abstract][Full Text] [Related]
11. Dopamine facilitates alpha-synuclein oligomerization in human neuroblastoma SH-SY5Y cells.
Yamakawa K; Izumi Y; Takeuchi H; Yamamoto N; Kume T; Akaike A; Takahashi R; Shimohama S; Sawada H
Biochem Biophys Res Commun; 2010 Jan; 391(1):129-34. PubMed ID: 19900407
[TBL] [Abstract][Full Text] [Related]
12. Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage.
Lev N; Melamed E; Offen D
Neurosci Lett; 2006 May; 399(1-2):27-32. PubMed ID: 16584840
[TBL] [Abstract][Full Text] [Related]
13. Alpha-synuclein knockdown attenuates MPP+ induced mitochondrial dysfunction of SH-SY5Y cells.
Wu F; Poon WS; Lu G; Wang A; Meng H; Feng L; Li Z; Liu S
Brain Res; 2009 Oct; 1292():173-9. PubMed ID: 19646423
[TBL] [Abstract][Full Text] [Related]
14. Immunoassay of in vitro activated human tissue transglutaminase.
Wolf J; Lachmann I; Wagner U; Osman A; Mothes T
Anal Biochem; 2011 Apr; 411(1):10-5. PubMed ID: 21146490
[TBL] [Abstract][Full Text] [Related]
15. Proteomic analysis of dopamine and α-synuclein interplay in a cellular model of Parkinson's disease pathogenesis.
Alberio T; Bossi AM; Milli A; Parma E; Gariboldi MB; Tosi G; Lopiano L; Fasano M
FEBS J; 2010 Dec; 277(23):4909-19. PubMed ID: 20977677
[TBL] [Abstract][Full Text] [Related]
16. α-Synuclein-induced mitochondrial dysfunction in isolated preparation and intact cells: implications in the pathogenesis of Parkinson's disease.
Bir A; Sen O; Anand S; Khemka VK; Banerjee P; Cappai R; Sahoo A; Chakrabarti S
J Neurochem; 2014 Dec; 131(6):868-77. PubMed ID: 25319443
[TBL] [Abstract][Full Text] [Related]
17. Raised calcium promotes α-synuclein aggregate formation.
Nath S; Goodwin J; Engelborghs Y; Pountney DL
Mol Cell Neurosci; 2011 Feb; 46(2):516-26. PubMed ID: 21145971
[TBL] [Abstract][Full Text] [Related]
18. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
Koo HJ; Choi MY; Im H
Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
[TBL] [Abstract][Full Text] [Related]
19. Cross-linking of cellular proteins by tissue transglutaminase during necrotic cell death: a mechanism for maintaining tissue integrity.
Nicholas B; Smethurst P; Verderio E; Jones R; Griffin M
Biochem J; 2003 Apr; 371(Pt 2):413-22. PubMed ID: 12533191
[TBL] [Abstract][Full Text] [Related]
20. Involvement of tissue transglutaminase in endothelin 1-induced hypertrophy in cultured neonatal rat cardiomyocytes.
Li X; Wei XL; Meng LL; Chi MG; Yan JQ; Ma XY; Jia YS; Liang L; Yan HT; Zheng JQ
Hypertension; 2009 Oct; 54(4):839-44. PubMed ID: 19635990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
